Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D I Jodrell

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
Biochemical Pharmacology|December 14, 1993
The in vivo metabolic stability of dipeptide analogues of the quinazoline antifolate, ICI 198583, in miceD I Jodrell, W Gibson, G M Bisset, et al.
British Journal of Cancer|October 1, 1994
Bolus/infusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma: are suboptimal dosages being used in the UK?D I Jodrell, L S Murray, N S Reed, et al.
The Pharmacogenomics Journal|June 15, 2007
ABCB1 genetic polymorphism influences the pharmacology of the new pyrrolobenzodiazepine derivative SJG-136R E Aird, M Thomson, J S Macpherson, et al.
Cancer Research|January 1, 1992
Use of adaptive control with feedback to individualize suramin dosingH I Scher, D I Jodrell, J M Iversen, et al.
The Journal of Pathology|June 26, 2002
Cyclin D1 overexpression in colorectal carcinoma in vivo is dependent on beta-catenin protein dysregulation, but not k-ras mutationN A C S Wong, R G Morris, A McCondochie, et al.
British Journal of Cancer|March 26, 1998
Dose-limiting neurotoxicity in a phase I study of penclomedine (NSC 388720, CRC 88-04), a synthetic alpha-picoline derivative, administered intravenouslyD I Jodrell, A Bowman, M Stewart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2001
Forearm blood flow and local responses to peptide vasodilators: a novel pharmacodynamic measure in the phase I trial of antagonist G, a neuropeptide growth factor antagonistS Clive, D J Webb, A MacLellan, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2000
A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weeklyL K Dawson, D I Jodrell, A Bowman, et al.
British Journal of Cancer|March 10, 1999
A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administrationD I Jodrell, A Bowman, R Rye, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancerD I Jodrell, W Oster, D J Kerr, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
Biochemical Pharmacology|December 14, 1993
The in vivo metabolic stability of dipeptide analogues of the quinazoline antifolate, ICI 198583, in miceD I Jodrell, W Gibson, G M Bisset, et al.
British Journal of Cancer|October 1, 1994
Bolus/infusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma: are suboptimal dosages being used in the UK?D I Jodrell, L S Murray, N S Reed, et al.
The Pharmacogenomics Journal|June 15, 2007
ABCB1 genetic polymorphism influences the pharmacology of the new pyrrolobenzodiazepine derivative SJG-136R E Aird, M Thomson, J S Macpherson, et al.
Cancer Research|January 1, 1992
Use of adaptive control with feedback to individualize suramin dosingH I Scher, D I Jodrell, J M Iversen, et al.
The Journal of Pathology|June 26, 2002
Cyclin D1 overexpression in colorectal carcinoma in vivo is dependent on beta-catenin protein dysregulation, but not k-ras mutationN A C S Wong, R G Morris, A McCondochie, et al.
British Journal of Cancer|March 26, 1998
Dose-limiting neurotoxicity in a phase I study of penclomedine (NSC 388720, CRC 88-04), a synthetic alpha-picoline derivative, administered intravenouslyD I Jodrell, A Bowman, M Stewart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2001
Forearm blood flow and local responses to peptide vasodilators: a novel pharmacodynamic measure in the phase I trial of antagonist G, a neuropeptide growth factor antagonistS Clive, D J Webb, A MacLellan, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2000
A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weeklyL K Dawson, D I Jodrell, A Bowman, et al.
British Journal of Cancer|March 10, 1999
A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administrationD I Jodrell, A Bowman, R Rye, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancerD I Jodrell, W Oster, D J Kerr, et al.
Pageof 6